Suven Pharmaceuticals Ltd, established in 1989 and headquartered in Hyderabad, Telangana, India, is a leading name in the bio-pharmaceutical industry. As a subsidiary of Berhyanda Limited, Suven has built a reputation for its strong focus on innovation, quality, and ethical business practices. The company operates across multiple segments, including Contract Research and Manufacturing Services (CRMS), Active Pharmaceutical Ingredients (APIs), Specialty Chemicals, and Formulated Drugs. With a global footprint that extends across India, the United States, Europe, and other international markets, Suven has cemented its position as a significant player in the pharmaceutical sector. Its product portfolio includes intermediates for new chemical entities, APIs, specialty chemicals, and formulated drugs, showcasing its commitment to high-quality and impactful solutions. Under the leadership of key figures such as Sudhir Kumar Singh (CEO), Himanshu Agarwal (CFO), and Cyndrella Carvalho (Head of Investor Relations), the company adheres to core values such as honesty, integrity, respect, and innovation. Suven fosters a culture of trust and community, emphasizing respect for individual rights and differences while striving to deliver excellence in its products and services. With continuous learning and adaptation, Suven Pharmaceuticals remains a dynamic force in advancing healthcare solutions globally.
Latest News on Suven Pharmaceuticals
Suven Pharmaceuticals Ltd, supported by Advent International, has made a significant strategic move by acquiring a 56% controlling stake in NJ Bio Inc, a US-based Contract Research, Development, and Manufacturing Organization (CRDMO). This acquisition, valued at $64.4 million, underscores Suven’s commitment to expanding its global footprint and enhancing its capabilities in the pharmaceutical and biotech sectors. The deal includes a primary equity infusion of $15 million, aimed at driving NJ Bio’s growth and innovation initiatives. This partnership is expected to strengthen Suven’s position in the high-value CRDMO space, enabling it to deliver advanced research and manufacturing solutions to clients worldwide.
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | |
| Promoters + | 60.00% | 60.00% | 50.10% | 50.10% | 50.10% |
| FIIs + | 10.01% | 10.14% | 9.54% | 9.80% | 10.70% |
| DIIs + | 14.13% | 15.94% | 17.24% | 17.42% | 16.95% |
| Government + | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public + | 15.85% | 13.93% | 23.11% | 22.67% | 22.26% |
| No. of Shareholders | 73,715 | 70,052 | 68,932 | 65,777 | 69,337 |
The shareholding pattern of Suven Pharmaceuticals Ltd has shown notable shifts over the past year. As of September 2023, promoters held a robust 60% stake, which significantly declined to 50.10% by March 2024 and remained steady thereafter. Foreign Institutional Investors (FIIs) maintained consistent involvement, with their share slightly fluctuating from 10.01% in September 2023 to 10.70% by September 2024. Domestic Institutional Investors (DIIs) increased their holdings during this period, rising from 14.13% in September 2023 to a peak of 17.42% in June 2024, before settling at 16.95% in September 2024.
The public shareholding demonstrated an opposite trend, increasing from 15.85% in September 2023 to 23.11% by March 2024, followed by a gradual decline to 22.26% in September 2024. Government ownership remained negligible at 0.01% throughout the year. Additionally, the number of shareholders decreased from 73,715 in September 2023 to a low of 65,777 in June 2024, before recovering slightly to 69,337 by September 2024.
Below are the trading platforms that you can use to purchase Suven Pharmaceuticals shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
| When | Maximum Price | Minimum Price |
| January 2025 | 1,297.05 | 997.73 |
| February 2025 | 1,310.16 | 1,007.81 |
| March 2025 | 1,337.67 | 1,028.98 |
| April 2025 | 1,324.42 | 1,018.79 |
| May 2025 | 1,285.85 | 989.11 |
| June 2025 | 1,343.71 | 1,033.62 |
| July 2025 | 1,317.37 | 1,013.36 |
| August 2025 | 1,358.11 | 1,044.70 |
| September 2025 | 1,374.41 | 1,057.24 |
| October 2025 | 1,410.14 | 1,084.72 |
| November 2025 | 1,445.39 | 1,111.84 |
| December 2025 | 1,510.44 | 1,161.87 |
As we step into 2025, Suven Pharmaceuticals Ltd is projected to see January prices ranging between ₹997.73 and ₹1,297.05, rising steadily through the year. By June, prices are expected to reach ₹1,033.62 to ₹1,343.71, with further growth anticipated in the later months. December is projected to peak at ₹1,510.44, with an expected minimum of ₹1,161.87.
| When | Maximum Price | Minimum Price |
| January 2026 | 1,555.75 | 1,196.73 |
| February 2026 | 1,516.86 | 1,166.81 |
| March 2026 | 1,547.19 | 1,190.15 |
| April 2026 | 1,578.77 | 1,214.44 |
| May 2026 | 1,563.14 | 1,202.41 |
| June 2026 | 1,602.22 | 1,232.47 |
| July 2026 | 1,570.80 | 1,208.31 |
| August 2026 | 1,619.38 | 1,245.68 |
| September 2026 | 1,651.77 | 1,270.59 |
| October 2026 | 1,694.71 | 1,303.63 |
| November 2026 | 1,737.08 | 1,336.22 |
| December 2026 | 1,780.51 | 1,369.62 |
As we move into 2026, Suven Pharmaceuticals Ltd is projected to begin January with prices expected between ₹1,196.73 and ₹1,555.75. Progressing through the year, prices are anticipated to rise steadily, reaching ₹1,232.47 to ₹1,602.22 by June. This growth is expected to continue, with September projected to see a range of ₹1,270.59 to ₹1,651.77. Finally, as we move towards December, Suven Pharmaceuticals Ltd’s prices are expected to peak at ₹1,369.62 on the lower end and ₹1,780.51 as the year’s highest.
| When | Maximum Price | Minimum Price |
| January 2027 | 1,798.31 | 1,383.32 |
| February 2027 | 1,844.42 | 1,418.79 |
| March 2027 | 1,916.36 | 1,474.12 |
| April 2027 | 1,878.78 | 1,445.22 |
| May 2027 | 1,824.06 | 1,403.12 |
| June 2027 | 1,906.14 | 1,466.26 |
| July 2027 | 1,868.77 | 1,437.51 |
| August 2027 | 1,926.56 | 1,481.97 |
| September 2027 | 1,993.99 | 1,533.84 |
| October 2027 | 2,045.84 | 1,573.72 |
| November 2027 | 2,096.98 | 1,613.06 |
| December 2027 | 2,149.41 | 1,653.39 |
| When | Maximum Price | Minimum Price |
| January 2028 | 2,192.40 | 1,686.46 |
| February 2028 | 2,248.61 | 1,729.70 |
| March 2028 | 2,336.31 | 1,797.16 |
| April 2028 | 2,290.50 | 1,761.92 |
| May 2028 | 2,223.78 | 1,710.60 |
| June 2028 | 2,323.85 | 1,787.58 |
| July 2028 | 2,278.29 | 1,752.53 |
| August 2028 | 2,348.75 | 1,806.73 |
| September 2028 | 2,430.96 | 1,869.97 |
| October 2028 | 2,494.16 | 1,918.59 |
| November 2028 | 2,556.52 | 1,966.55 |
| December 2028 | 2,620.43 | 2,015.71 |
| When | Maximum Price | Minimum Price |
| January 2029 | 2,672.84 | 2,056.03 |
| February 2029 | 2,741.37 | 2,108.75 |
| March 2029 | 2,848.29 | 2,190.99 |
| April 2029 | 2,792.44 | 2,148.03 |
| May 2029 | 2,711.10 | 2,085.46 |
| June 2029 | 2,833.10 | 2,179.31 |
| July 2029 | 2,777.55 | 2,136.58 |
| August 2029 | 2,863.46 | 2,202.66 |
| September 2029 | 2,963.68 | 2,279.75 |
| October 2029 | 3,040.73 | 2,339.03 |
| November 2029 | 3,116.75 | 2,397.50 |
| December 2029 | 3,194.67 | 2,457.44 |
| When | Maximum Price | Minimum Price |
| January 2030 | 3,258.56 | 2,506.59 |
| February 2030 | 3,342.12 | 2,570.86 |
| March 2030 | 3,472.46 | 2,671.12 |
| April 2030 | 3,404.37 | 2,618.75 |
| May 2030 | 3,305.21 | 2,542.47 |
| June 2030 | 3,453.95 | 2,656.88 |
| July 2030 | 3,386.23 | 2,604.79 |
| August 2030 | 3,490.95 | 2,685.35 |
| September 2030 | 3,613.14 | 2,779.34 |
| October 2030 | 3,707.08 | 2,851.60 |
| November 2030 | 3,799.76 | 2,922.89 |
| December 2030 | 3,894.75 | 2,995.96 |
In 2030, Suven Pharmaceuticals Ltd is projected to show substantial growth in its stock prices. In January, the expected prices range from ₹2,506.59 to ₹3,258.56. By mid-year, June is anticipated to reflect a range of ₹2,656.88 to ₹3,453.95, indicating steady progress. As we advance into the later months, September is expected to see prices between ₹2,779.34 and ₹3,613.14. Finally, December 2030 is projected to conclude the year with prices ranging from ₹2,995.96 to ₹3,894.75, reflecting a strong upward trajectory for Suven Pharmaceuticals Ltd.
Suven Pharmaceuticals Financial Condition
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
| Sales + | 834 | 1,010 | 1,320 | 1,340 | 1,051 | 961 |
| Expenses + | 449 | 567 | 738 | 766 | 645 | 638 |
| Operating Profit | 385 | 443 | 582 | 574 | 406 | 323 |
| OPM % | 46% | 44% | 44% | 43% | 39% | 34% |
| Other Income + | 66 | 68 | 133 | 46 | 62 | 64 |
| Interest | 23 | 12 | 9 | 13 | 7 | 8 |
| Depreciation | 24 | 32 | 39 | 48 | 55 | 60 |
| Profit before tax | 405 | 468 | 668 | 560 | 406 | 319 |
| Tax % | 22% | 23% | 32% | 27% | 26% | |
| Net Profit + | 317 | 362 | 454 | 411 | 300 | 243 |
| EPS in Rs | 12.45 | 14.23 | 17.83 | 16.16 | 11.8 | 9.56 |
| Dividend Payout % | 20% | 14% | 28% | 37% | 0% |
The financial performance of Suven Pharmaceuticals Ltd over the years reflects notable trends. Between March 2020 and March 2024, the company’s sales experienced growth from ₹834 crore in March 2020 to ₹1,340 crore in March 2023, before declining to ₹1,051 crore in March 2024. The trailing twelve months (TTM) sales further decreased to ₹961 crore, indicating recent challenges.
Operating Profit showed a similar trajectory, rising from ₹385 crore in March 2020 to ₹574 crore in March 2023, but declining to ₹406 crore in March 2024 and further to ₹323 crore TTM. Correspondingly, the Operating Profit Margin (OPM%) has seen a consistent decline from 46% in March 2020 to 34% TTM, highlighting rising cost pressures.
Net Profit increased from ₹317 crore in March 2020 to ₹454 crore in March 2022 but has since decreased to ₹300 crore in March 2024 and ₹243 crore TTM. Earnings per share (EPS) followed this trend, peaking at ₹17.83 in March 2022 and falling to ₹11.8 in March 2024 and ₹9.56 TTM.
Suven Pharmaceuticals maintained a dividend payout policy, with percentages ranging from 14% to 37% during the period, but notably, no dividend payout was recorded in March 2024.
FAQS
As of December 20th, 2024, the share price of Suven Pharmaceuticals is around INR ₹1,185.
It is unlikely for the share price of Suven Pharmaceuticals to reach INR 5000 by 2025. Such a target would require a massive and unrealistic growth rate.
As per our analysis, Suven Pharmaceuticals in 2025 is expected to trade between ₹989.11 and ₹1,510.44.
As per our analysis, Suven Pharmaceuticals share price target for 2030 would be somewhere between ₹2,506.59 and ₹3,894.75.
Also Read:
- Valor Estate Share Price Target 2025, 2026 to 2030
- MOIL Share Price Target 2025, 2026 to 2030
- Action Construction Equipment Share Price Target 2025, 2026 to 2030
Conclusion
In conclusion, Suven Pharmaceuticals has demonstrated strong financial health with impressive profitability metrics, strong liquidity, and efficient utilization of resources. The company’s recent strategic acquisition of NJ Bio Inc. marks a significant milestone in expanding its market reach and capabilities in advanced therapeutic solutions, particularly antibody-drug conjugates. This move aligns with Suven’s ambitious growth strategy to organically and inorganically scale its operations, positioning the company for sustained success and leadership in the pharmaceutical industry. With a clear vision and sound financial foundation, Suven Pharmaceuticals is poised for long-term value creation and innovation.
What did we learn?
- 1 Latest News on Suven Pharmaceuticals
- 2 Shareholdings Patterns of Suven Pharmaceuticals
- 3 How to Purchase Suven Pharmaceuticals Shares?
- 4 Suven Pharmaceuticals Share Price Prediction 2025, 2026 to 2030
- 4.1 Suven Pharmaceuticals Share Price Target 2025
- 4.2 Suven Pharmaceuticals Share Price Target 2026
- 4.3 Suven Pharmaceuticals Share Price Prediction 2027
- 4.4 Suven Pharmaceuticals Share Price Prediction 2028
- 4.5 Suven Pharmaceuticals Share Price Target 2029
- 4.6 Suven Pharmaceuticals Share Price Prediction 2030
- 5 Suven Pharmaceuticals Financial Condition
- 6 FAQS
- 7 Conclusion
